A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Phase of Trial: Phase II/III
Latest Information Update: 19 Feb 2019
At a glance
- Drugs Guselkumab (Primary) ; Guselkumab (Primary) ; Ustekinumab; Ustekinumab
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms GALAXI; GALAXI 1; GALAXI 2; GALAXI 3
- Sponsors Janssen Research & Development
- 12 Feb 2019 Planned End Date changed from 23 Oct 2024 to 1 Feb 2025.
- 04 Sep 2018 Planned primary completion date changed from 16 Aug 2022 to 3 Jun 2022.
- 31 Aug 2018 Biomarkers information updated